Skip to main content

Table 3 Outcome parameter comparing patients with DOAC and VKA pretreatment

From: MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists

 DOAC pretreatment (N = 75)VKA pretreatment (N = 61)PConfirmed therapeutic DOAC (N = 35)Confirmed therapeutic VKA (N = 45)P
Clinical outcome
 NIHSS at 24 h2 (1–4)3 (0–7)0.3593 (1–5)4 (0–8)0.565
 sICH ECASS-II1/75 (1.3%)1/61 (1.6%)0.73501/45 (2.2%)0.298
 Duration of hospital stay, days4 (2–8)4 (2–8)0.3454 (3–7)4 (2–8)0.359
 90d mRS1.5 (1–3)3 (1.5–4)0.0011 (1–2)3 (2–6)< 0.001
 90d recurrent stroke2/75 (2.7%)4/61 (6.6%)0.25503/45 (6.7%)0.185
Imaging
 Diameter axis 1, initial DWI, mm18 (11–36)20 (7–36)0.60719 (12–33)13 (6–26)0.111
 Diameter axis 2, initial DWI, mm10 (6–19)9 (5–23)0.78012 (6–19)7 (4–16)0.127
 Diameter hypoperfusion axis 1, mm80 (38–118), N = 4049 (36–67), N = 370.03983 (27–118), N = 1649 (36–66), N = 130.079
 Diameter hypoperfusion axis 2, mm34 (18–40), N = 4034 (14–40), N = 370.49434 (20–46), N = 1633 (13–38), N = 130.318
 DWI/Perfusion Mismatch  0.443  0.714
  - None39/66 (59.1%)29/53 (54.7%) 17/28 (60.7%)26/40 (65.0%) 
  - Small4/66 (6.1%)8/53 (15.1%) 1/28 (3.6%)3/40 (7.5%) 
  - Medium4/66 (6.1%)3/53 (5.7%) 2/28 (7.1%)1/40 (2.5%) 
  - Large19/66 (28.8%)13/53 (24.5%) 8/28 (28.6%)10/40 (25%) 
 Diameter axis 1, final FLAIR18 (12–38)27 (8–50)0.40918 (13–23)20 (6–52)0.945
 Diameter axis 2, final FLAIR10 (6–22)14 (7–25)0.39710 (6–22)11 (5–25)0.908
 Occlusion, any22/75 (29.3%)23/61 (37.7%)0.3619/35 (25.7%)14/45 (31.1%)0.628
 Target occlusion for EVT20/75 (26.7%)17/61 (27.9%)1.0009/35 (25.7%)9/45 (20.0%)0.596
 Thrombus length8 (6–20), N = 1913 (7–24), N = 130.38815 (6–21), N = 711 (4–30), N = 60.836
 Multiple Lesions31/56 (55.4%)24/49 (49.0%)0.56010/21 (47.6%)20/41 (48.8%)1.000
 ICH, Heidelberg at follow up  0.024  0.126
  - 1a5/75 (6.7%)3/61 (4.9%) 4/35 (11.4%)3/45 (6.7%) 
  - 1b07/61 (11.5%) 05/45 (11.1%) 
  - 201/61 (1.6%) 00 
  - 3c1/75 (1.3%)0 1 (2.9%)0 
  1. DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, NIHSS National Institute of Health Stroke Scale, sICH ECASS II symptomatic intracranial hemorrhage according to the European Co-operative Acute Stroke Study-II definition, mRS modified Rankin Scale, DWI Diffusion weighted imaging, FLAIR Fluid attenuated inversion recovery sequence, EVT Endovascular stroke treatment, ICH Intracranial hemorrhage